Skip to main content
All lobbying filings

EXELIXIS INC.

Lobbying for EXELIXIS INC.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $560,000.00 expenses · posted Jul 20, 2026

Official filing document

 Bills named in this filing 2
 Lobbying activity 2
Health Issues

Proposals related to drug pricing, including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, to include CMMIs GUARD and GLOBE models, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. Development and implementation of national security policies impacting biotechnology, including regulatory frameworks that may affect cross-border investments, research collaborations, and business operations

Taxation/Internal Revenue Code

Federal tax policy issues affecting the biopharmaceutical industry, including provisions related to business taxation, research and development incentives, and broader fiscal legislation.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem